These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
668 related articles for article (PubMed ID: 26450624)
1. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624 [TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794 [TBL] [Abstract][Full Text] [Related]
4. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related]
5. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
6. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333 [TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843 [TBL] [Abstract][Full Text] [Related]
8. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900 [TBL] [Abstract][Full Text] [Related]
9. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging. Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178 [TBL] [Abstract][Full Text] [Related]
10. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. Ohno M; Ohkuri T; Kosaka A; Tanahashi K; June CH; Natsume A; Okada H J Immunother Cancer; 2013; 1():21. PubMed ID: 24829757 [TBL] [Abstract][Full Text] [Related]
14. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640 [No Abstract] [Full Text] [Related]
15. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell. Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736 [TBL] [Abstract][Full Text] [Related]
16. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927 [TBL] [Abstract][Full Text] [Related]
17. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369 [TBL] [Abstract][Full Text] [Related]
18. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related]
20. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]